Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CPS1 | P31327 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29785358 | 1.00 | EGFR (0.48) | EGFRKDRCYP1A2CYP1A1CYP1B1 | |
| SCHEMBL30180094 | 0.84 | CA12 (0.46) | CYP1A2CYP1A1CYP1B1CA12CA1 | |
| SCHEMBL1042775 | 0.84 | CA12 (0.46) | CYP1A2CYP1A1CYP1B1CA12CA1 | |
| SCHEMBL876226 | 0.84 | CYP11B1 (0.49) | EGFRKDRCA12CA1CA2 | |
| SCHEMBL30250475 | 0.80 | CA1 (0.53) | CYP1A2CYP1A1CYP1B1CA12CA1 | |
| SCHEMBL1134723 | 0.80 | CA1 (0.53) | CYP1A2CYP1A1CYP1B1CA12CA1 | |
| SCHEMBL254529 | 0.78 | CA12 (0.50) | CYP1A2CYP1A1CYP1B1CA12CA1 | |
| SCHEMBL29513208 | 0.78 | CA12 (0.50) | CYP1A2CYP1A1CYP1B1CA12CA1 | |
| SCHEMBL14874698 | 0.78 | SNCA (0.37) | EGFRKDRCYP1A2CYP1A1CYP1B1 | |
| SCHEMBL2171833 | 0.78 | EGFR (0.43) | EGFRKDRSLC6A4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396261-A | Fluoro-spiro-aryl hole transport material for perovskite solar cell, and preparation method and application thereof | 宁波维海云光电科技有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-12583878-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4665458-A1 | INHIBITING ALPHA V BETA8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BORAH INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-12460128-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2025-11-04 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| US-5536443-A | DUTERIUM CONTAINING COMPOUNDS FOOR ELECTROOPTICAL APPARATUS | DAINIPPON INK & CHEMICALS, INC. (JP) | 1996-07-16 | — | — | US | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
| US-5474707-A | Electrooptic display | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1995-12-12 | — | — | US | disclosed |
| EP-0637623-A1 | Cyclic hydrocarbon derivative and liquid crystal composition containing the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1995-02-08 | — | — | EP | disclosed |
| EP-0193055-B1 | ANTITUMORALS(1,2-DIPHENYL-ETHYLENE DIAMINE)-PLATINUM (II) COMPLEXES | ASTA Pharma AG (DE) | 1990-05-16 | — | — | EP | disclosed |
| EP-0341686-A2 | Novel halogen-containing ester compounds, and their intermediates, and method of producing the same as well as liquid crystal compositions containing the same and light switching elements | JAPAN ENERGY CORPORATION (JP) | 1989-11-15 | — | — | EP | disclosed |
| US-4730068-A | SPECIAL EFFECT ON BREAST CANCER | ASTA-WERKE AKTIENGESELLSCHAFT (DE) | 1988-03-08 | — | — | US | disclosed |
| CN-86100815-A | The preparation method who suppresses (1, the 2-diphenyl ethylene diamine)-platinum (II) complex compound of tumour | — | 1986-11-26 | — | — | CN | disclosed |
| EP-0193055-A1 | Antitumorals(1,2-diphenyl-ethylene diamine)-platinum (II) complexes | ASTA Pharma AG (DE) | 1986-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | JAK3, JAK1, JAK2 | EGFR 2148/4885KDR 2313/4885CYP1A2 1866/4885 |
| US-12460128-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, ICOSLG | EGFR 1603/4885KDR 1834/4885CYP1A2 1002/4885 |
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | MAPK6, MAPK3, MAPK1 | EGFR 82/4885KDR 818/4885CYP1A2 877/4885 |
| US-12583878-B2 | Organic electroluminescent materials and devices | SOD1, SSB, ROS1 | EGFR 24/4885KDR 1142/4885CYP1A2 3962/4885 |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS1, GYS2, GBA1 | EGFR 3921/4885KDR 4601/4885CYP1A2 2531/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | EGFR 4367/4885KDR 746/4885CYP1A2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.